Konrad Pagacz

Konrad Pagacz

Auto-generated profile, based on publicly available information

Konrad Pagacz

Department of Biostatistics and Translational Medicine, Medical University of Lodz, Lodz, Poland

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2020 in BMC Bioinformatics
Verified
Journal Article
Open access
PDF file
SGSzymon Grabia
Szymon Grabia
USUrszula Smyczynska
Urszula Smyczynska
KPKonrad Pagacz
Konrad Pagacz
WFWojciech Fendler
Wojciech Fendler
Background: Multi-gene expression assays are an attractive tool in revealing complex regulatory mechanisms in living organisms. Normalization is an indispensable step of data analysis in all those studies, since it removes unwanted, non-biological variability from data. In targeted qPCR assays it is typically performed with respect to prespecified reference genes, but the lack of robust strategy of their selection is reported in literature, especially in studies concerning circulating microRNAs (miRNA). Unfortunately, this problem impedes translation of scientific discoveries on miRNA biomarkers into widely available laboratory assays. Previous studies concluded that averaged expressions of multi-miRNA combinations are more stable references than single genes. However, due to the number of such combinations the computational load is considerable and may be hindering for objective reference selection in large datasets. Existing implementations of normalization algorithms (geNorm, NormFinder and BestKeeper) have poor performance and may require days to compute stability values for all potential reference as the evaluation is performed sequentially. Results: We designed NormiRazor - an integrative tool which implements those methods in a parallel manner on a graphics processing unit (GPU) using CUDA platform. We tested our approach on publicly available miRNA expression datasets. As a result, the times of executions on 8 datasets containing from 50 to 400 miRNAs (subsets of GSE68314) decreased 18.7 ±0.6 (mean ±SD), 104.7 ±4.2 and 76.5 ±2.2 times for geNorm, BestKeeper and NormFinder with respect to previous Python implementation. To allow for easy access to normalization pipeline for biomedical researchers we implemented NormiRazor as an online platform where a user could normalize their datasets based on the automatically selected references. It is available at norm.btm.umed.pl, together with instruction manual and exemplary datasets. Conclusions: NormiRazor allows for an easy, informed choice of reference genes for qPCR transcriptomic studies. As such it can improve comparability and repeatability of experiments and in longer perspective help translate newly discovered biomarkers into readily available assays.

13 April 2018 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
KPKonrad Pagacz
Konrad Pagacz
Konrad StawiskiKonrad Stawiski
Konrad Stawiski
ASAgnieszka Szadkowska
Agnieszka Szadkowska
WMWojciech Mlynarski
Wojciech Mlynarski
WFWojciech Fendler
Wojciech Fendler

3 April 2019 in Pediatric Diabetes
Verified
Journal Article
Closed access
PDF file
AMArkadisz Michalak
Arkadisz Michalak
KPKonrad Pagacz
Konrad Pagacz
WMWojciech Młynarski
Wojciech Młynarski
ASAgnieszka Szadkowska
Agnieszka Szadkowska
WFWojciech Fendler
Wojciech Fendler

1 March 2018 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
PDPiotr Donizy
Piotr Donizy
KPKonrad Pagacz
Konrad Pagacz
JMJakub Marczuk
Jakub Marczuk
WFWojciech Fendler
Wojciech Fendler
AMAdam Maciejczyk
Adam Maciejczyk
RMRafał Matkowski
Rafał Matkowski

Background:
FOXP1 is a pleiotropic protein that plays important roles in immune responses (B-cell development regulation and differentiation of monocyte), organ development (cardiac valves, lung, and esophagus), and neuronal development. Besides being the primary regulator of normal human tissue development, FOXP1 also plays a role in tumorigenesis. However, the potential value of FOXP1 expression in tumor prognosis remains controversial. FOXP1 expression was assessed in tumor cells (TCs) and stromal cells (SCs) of cutaneous melanomas with the aim of analyzing the associations between FOXP1 expression and clinicopathological characteristics. We believe this article to be the first report analyzing the correlations between FOXP1 expression and clinicopathological, as well as histological, characteristics in melanoma. Materials and methods: In total, 96 formalin-fixed, paraffin-embedded primary cutaneous melanoma tissue specimens were subjected to immunohistochemical analysis for FOXP1, and the results were correlated with classical clinicopathological features and patient survival. Results: FOXP1 overexpression in TCs was strongly associated with the presence of metastases in sentinel lymph nodes (p=0.0003, OR=11.66) and positive status of regional lymph nodes (p=0.0006, OR=22.15). In 96% (52 of 54) of patients presenting with low FOXP1 expression, no clinical or histopathological features of lymphatic dissemination were observed. However, thinner and nonulcerated tumors were reported to have increased numbers of FOXP1-positive SCs. In addition, a strong association was observed between FOXP1 upregulation in SCs and the absence of regional lymph node metastases. There was a significant correlation between FOXP1 upregulation in TCs and shorter cancer-specific overall survival (log-rank test, p=0.0040) and disease-free survival (log-rank test, p=0.0021). FOXP1 expression was confirmed in multivariate analysis as a factor that significantly unfavorably impacts prognosis in melanoma patients (HR=3.14, p=0.0299, adjusted for age, Breslow thickness, and sex). Conclusion: The findings from this study indicate that FOXP1 has a major role in melanoma progression, which makes it a candidate for molecular target-based cancer therapy.

5 April 2017 in Nursing and Public Health
Verified
Journal Article
Open access
KMKatarzyna Mendyk
Katarzyna Mendyk
KAKinga Antos-Latek
Kinga Antos-Latek
MKMonika Kowalik
Monika Kowalik
KPKonrad Pagacz
Konrad Pagacz
MLMarcin Lewicki
Marcin Lewicki
EOEwa Obel
Ewa Obel

4 December 2018 in Diabetes Technology & Therapeutics
Verified
Journal Article
Closed access
PKPrzemysław Kucharski
Przemysław Kucharski
KPKonrad Pagacz
Konrad Pagacz
ASAgnieszka Szadkowska
Agnieszka Szadkowska
WMWojciech Młynarski
Wojciech Młynarski
ARAndrzej Romanowski
Andrzej Romanowski
WFWojciech Fendler
Wojciech Fendler
Background: Continuous glucose monitoring (CGM) is a method of estimating blood glucose values from those recorded in the interstitial fluid. Because increasingly longer CGM measurements are possible, errors and data loss become more and more likely and potentially more damaging to accurate calculations of glycemic variability (GV) indices. Our research investigates the resistance of the CGM recording to data loss. Methods: We collected 71 CGM recordings (duration of min: 2, max: 265, median: 42 days) from patients with type 1 diabetes and used three algorithms to introduce missing data. We calculated mean and standard deviation (SD) of absolute percentage error of 12 variability indices and correlated those with the percentage of missing data and duration of the measurements. Results: Mean absolute percentage error of variability indices increased linearly with the percentage of missing data along with SD of absolute percentage error. Except for mean amplitude of glycemic excursions and time spent in hypoglycemia, all absolute errors never exceeded 25%, while mean absolute errors stayed below 5%. The gradient removal algorithm introduced errors larger than the single datapoint and block removal algorithms. The absolute percentage error of variability indices correlated negatively with the duration of the CGM measurements. Conclusions: Standard GV measurements in long-term glucose monitoring are robustly resistant to data loss.